MA16.08 Impact of Site of CAN-2409 Injection Plus Continued Immune Checkpoint Inhibitor (ICI) In CI-resistant stage III/IV NSCLC
Year: 2024
Type: conference-abstract
Source: Journal of Thoracic Oncology
Authors: D. Sterman, C. Aggarwal, E.R. Alesi, F. Maldonado, R. Mehra, C. Bestvina, J.S. Reisenauer, L.K. Swartz, S. Puri, O. Ibrahim, G. Eapen, C. Duault, D.M. Del Valle, S. Kim-Schulze, E. Gonzalez-Kozlova, S. Gnjatic, A. Manzanera, L. Lopez, J. Dwyer, S. Rao, G. Nichols, F. Barone, P.P. Tak
Institutions: New York University, University of Pennsylvania, Virginia Commonwealth University, Vanderbilt University Medical Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Chicago, Mayo Clinic, Veterans Health Administration, Hunter Holmes McGuire VA Medical Center, Huntsman Cancer Institute, UConn Health, Stanford Medicine, Stanford University, Icahn School of Medicine at Mount Sinai, Candel Therapeutics (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4403410325